| Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations KA Janeway, SY Kim, M Lodish, V Nosé, P Rustin, J Gaal, PLM Dahia, ... Proceedings of the National Academy of Sciences 108 (1), 314-318, 2011 | 663 | 2011 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 476 | 2016 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ... European journal of cancer 109, 36-50, 2019 | 469 | 2019 |
| Cancer screening recommendations for individuals with Li-Fraumeni syndrome CP Kratz, MI Achatz, L Brugieres, T Frebourg, JE Garber, MLC Greer, ... Clinical Cancer Research 23 (11), e38-e45, 2017 | 456 | 2017 |
| Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma JA Perry, A Kiezun, P Tonzi, EM Van Allen, SL Carter, SC Baca, ... Proceedings of the National Academy of Sciences 111 (51), E5564-E5573, 2014 | 431 | 2014 |
| Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), 2016 | 378 | 2016 |
| Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic SA Boikos, AS Pappo, JK Killian, MP LaQuaglia, CB Weldon, S George, ... JAMA oncology 2 (7), 922-928, 2016 | 377 | 2016 |
| Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor JK Killian, SY Kim, M Miettinen, C Smith, M Merino, M Tsokos, M Quezado, ... Cancer discovery 3 (6), 648-657, 2013 | 353 | 2013 |
| Future directions in the treatment of osteosarcoma MW Bishop, KA Janeway, R Gorlick Current opinion in pediatrics 28 (1), 26-33, 2016 | 295 | 2016 |
| Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects KA Janeway, HE Grier The lancet oncology 11 (7), 670-678, 2010 | 261 | 2010 |
| Von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood SP Rednam, A Erez, H Druker, KA Janeway, J Kamihara, WK Kohlmann, ... Clinical Cancer Research 23 (12), e68-e75, 2017 | 236 | 2017 |
| Differentiation of NUT midline carcinoma by epigenomic reprogramming BE Schwartz, MD Hofer, ME Lemieux, DE Bauer, MJ Cameron, NH West, ... Cancer research 71 (7), 2686-2696, 2011 | 211 | 2011 |
| Pediatric KIT–Wild-Type and Platelet-Derived Growth Factor Receptor α–Wild-Type Gastrointestinal Stromal Tumors Share KIT Activation but not Mechanisms of Genetic Progression … KA Janeway, B Liegl, A Harlow, C Le, A Perez-Atayde, H Kozakewich, ... Cancer research 67 (19), 9084-9088, 2007 | 210 | 2007 |
| Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study MH Harris, SG DuBois, JLG Bender, AR Kim, BD Crompton, E Parker, ... JAMA oncology 2 (5), 608-615, 2016 | 203 | 2016 |
| Children's Oncology Group's 2013 blueprint for research: bone tumors R Gorlick, K Janeway, S Lessnick, RL Randall, N Marina, ... Pediatric blood & cancer 60 (6), 1009-1015, 2013 | 198 | 2013 |
| Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib KA Janeway, KH Albritton, AD Van Den Abbeele, GZ D'Amato, ... Pediatric blood & cancer 52 (7), 767-771, 2009 | 179 | 2009 |
| Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group KA Janeway, DA Barkauskas, MD Krailo, PA Meyers, CL Schwartz, ... Cancer 118 (18), 4597-4605, 2012 | 178 | 2012 |
| Rationale and design of the targeted agent and profiling utilization registry study PK Mangat, S Halabi, SS Bruinooge, E Garrett-Mayer, A Alva, ... JCO precision oncology 2, 1-14, 2018 | 162 | 2018 |
| Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group … JP Lagmay, MD Krailo, H Dang, AR Kim, DS Hawkins, O Beaty III, ... Journal of Clinical Oncology 34 (25), 3031, 2016 | 157 | 2016 |
| Toward a drug development path that targets metastatic progression in osteosarcoma C Khanna, TM Fan, R Gorlick, LJ Helman, ES Kleinerman, PC Adamson, ... Clinical Cancer Research 20 (16), 4200-4209, 2014 | 155 | 2014 |
